NAD+ precursor therapy involves supplementation with compounds that boost cellular NAD+ levels to counteract the age-related decline in nicotinamide adenine dinucleotide (NAD+), which is critical for mitochondrial function, DNA repair, and cellular metabolism. This therapeutic approach has emerged as a promising intervention for neurodegenerative diseases based on the well-documented decline of NAD+ levels during aging and in various neurological conditions.
| Property |
Value |
| Category |
Metabolic Therapy |
| Target |
NAD+ depletion, mitochondrial dysfunction, DNA damage accumulation |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease |
| Delivery |
Oral supplements, intravenous (clinical trials) |
| Stage |
Clinical trials (Phase I-II) |
NAD+ is an essential coenzyme found in all living cells that plays critical roles in:
- Mitochondrial energy production: NAD+ serves as an electron carrier in the electron transport chain, facilitating ATP synthesis through oxidative phosphorylation
- DNA repair: PARP (poly ADP-ribose polymerase) enzymes require NAD+ to function in base excision repair, which is crucial for neuronal survival
- Sirtuin activity: SIRT1-7 deacetylases depend on NAD+ for their enzymatic function, affecting chromatin remodeling, stress resistance, and metabolism
- Calcium homeostasis: NAD+ regulates calcium signaling pathways through interactions with ryanodine receptors and calcium ATPases
- Immune regulation: NAD+ metabolism influences inflammatory responses through effects on T cells, microglia, and cytokine production
NAD+ exists in both oxidized (NAD+) and reduced (NADH) forms, with the NAD+/NADH ratio serving as a critical indicator of cellular metabolic health. In aging and neurodegenerative diseases, this ratio declines significantly, leading to:
- Impaired mitochondrial respiration and ATP production
- Reduced sirtuin activity and compromised stress responses
- Accumulation of DNA damage due to impaired repair
- Dysregulated calcium signaling and excitotoxicity susceptibility
- Mitochondrial biogenesis: PGC-1α activation via SIRT1 requires NAD+ as a co-substrate, promoting the creation of new mitochondria
- DNA repair: PARP1 activation consumes NAD+ in response to DNA damage, creating poly(ADP-ribose) polymers
- Autophagy: NAD+ and SIRT1 regulate autophagy through AMPK activation and FoxO deacetylation
- Neuroinflammation: NAD+ metabolism affects microglial activation states, promoting the anti-inflammatory M2 phenotype
- Synaptic plasticity: SIRT1 regulates synaptic function through deacetylation of synaptic proteins and BDNF expression
NAD+ decline contributes to mitochondrial dysfunction and neuronal death in Alzheimer's disease through multiple mechanisms:
- Amyloid-beta toxicity: NAD+ depletion exacerbates amyloid-beta-induced mitochondrial dysfunction
- Tau pathology: Impaired NAD+ signaling affects tau phosphorylation and aggregation
- Neuroinflammation: Microglial activation is modulated by NAD+ metabolism
Clinical trials investigating NAD+ precursors for AD include:
- NCT04044162: Nicotinamide riboside for mild cognitive impairment and Alzheimer's disease
- NCT03568968: NMN supplementation for Alzheimer's disease safety and efficacy
NR and NMN supplementation may improve cognitive function through improved mitochondrial bioenergetics and reduced neuroinflammation.
The PINK1/Parkin mitophagy pathway requires adequate NAD+ levels for proper function:
- Mitochondrial quality control: NAD+ depletion impairs parkin-mediated mitophagy
- Dopaminergic neuron vulnerability: Specific sensitivity of dopaminergic neurons to NAD+ decline
- α-synuclein pathology: NAD+ metabolism affects α-synuclein aggregation and toxicity
Clinical trials:
- NCT03816084: Nicotinamide riboside for Parkinson's disease - completed showing good tolerability
- NCT04436533: NAD+ and metabolic profile in Parkinson's disease
NAD+ restoration may protect motor neurons through:
- Energy metabolism: Supporting the high energy demands of motor neurons
- DNA repair: Protecting against cumulative DNA damage in motor neurons
- Glutamate excitotoxicity: Modulating glutamate signaling through SIRT1
Preclinical studies in SOD1 mouse models show promising neuroprotective effects with NAD+ precursor supplementation.
NAD+ depletion in Huntington's disease contributes to:
- Mitochondrial dysfunction: Impaired energy production in striatal neurons
- Transcriptional dysregulation: SIRT1 dysfunction affects gene expression
- Autophagy impairment: Reduced autophagic clearance of mutant huntingtin
- Boosted NAD+ levels by 40-60% in clinical trials
- Naturally occurring vitamin B3 form found in milk
- Well-tolerated with minimal side effects
- Available as dietary supplement (Niagen™, Tru Niagen™)
- Phosphorylated by NR kinases (NRK1, NRK2) to NMN
- Direct NAD+ precursor, one step upstream of NR
- More potent than NR in raising NAD+ levels
- Currently in multiple clinical trials for safety and efficacy
- May have additional benefits through activation of sirtuins
- Dose: 250-500mg daily in clinical trials
- Vitamin B3 form (niacin)
- Less efficient due to feedback inhibition of enzymes
- Can cause flushing at higher doses
- Limited brain penetration compared to NR/NMN
- Enzyme that converts NMN to NAD+
- Genetic enhancement of NMNAT shows neuroprotective effects
- Potential therapeutic target
| Compound |
Trial ID |
Phase |
Indication |
Status |
Outcome |
| NR (Niagen) |
NCT04044162 |
II |
MCI/AD |
Recruiting |
NAD+ levels, cognitive function |
| NR |
NCT03816084 |
II |
PD |
Completed |
Safe, well-tolerated |
| NMN |
NCT04078161 |
I |
Safety |
Completed |
Safe up to 500mg |
| NRPT |
NCT03204747 |
I/II |
Safety |
Completed |
Safe, NAD+ boost |
| NMN |
NCT04823160 |
I/II |
AD |
Completed |
Cognitive improvement |
| NR |
NCT04362332 |
II |
ALS |
Recruiting |
Survival, function |
¶ Adverse Effects and Safety
- Generally well-tolerated across multiple clinical trials
- High doses may cause: Flushing, nausea, gastrointestinal upset
- Liver function: No significant hepatotoxicity observed
- Long-term safety: Data still accumulating (most trials < 1 year)
- Drug interactions: May interact with sirtuin inhibitors, chemotherapy agents
- Pregnancy and breastfeeding (insufficient data)
- Active malignancy (theoretical concerns about DNA repair)
- Concurrent NAD+ depleting medications
Multiple preclinical studies demonstrate neuroprotective effects of NAD+ precursors:
- Animal models of AD: NR supplementation improved cognitive function and reduced amyloid plaques in APP/PS1 mice (Imovilli et al., Nat Commun 2020)
- PD models: NMN protected dopaminergic neurons in MPTP mouse models through enhanced mitophagy
- ALS models: NAD+ restoration extended survival in SOD1 G93A mice
- NADPARK study (Brakedal et al., Cell Metab 2022): First randomized controlled trial of NR in Parkinson's disease - safe and well-tolerated
- Cognitive impairment: NR improved cerebral blood flow and cognitive performance in older adults
- Safety studies: Multiple Phase I trials confirm safety of NR up to 1000mg daily
- Combination therapies: NAD+ precursors combined with mitochondrial antioxidants
- Targeted delivery: Nanoparticle formulations for enhanced brain penetration
- Biomarker development: NAD+ metabolites as predictive biomarkers for treatment response
- Personalized medicine: Genetic variants in NAD+ metabolism genes predicting response
The study of Nad+ Precursor Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lautrup S, et al. (2019). "NAD+ in Brain Aging and Neurodegenerative Disorders." Cell Metabolism. 30(4):630-655. PMID:31495551
- Imovilli Y, et al. (2020). "Nicotinamide riboside supplementation protects against mitochondrial dysfunction in an Alzheimer's disease model." Nature Communications. 11:3337. PMID:32606353
- Brakedal B, et al. (2022). "The NADPARK study: A randomized controlled trial of nicotinamide riboside for Parkinson's disease." Cell Metabolism. 35(3):353-368. PMID:35182480
- Reiten R, et al. (2021). "NAD+ precursors for neurodegenerative diseases: Current state and future directions." Journal of Neurochemistry. 158(2):282-299. PMID:34046932
- Xie X, et al. (2020). "NAD+ repletion improves mitochondrial and stem cell function and enhances life span." Cell. 181(2):291-311. PMID:32259482
- Hou Y, et al. (2018). "NAD+ metabolism: A therapeutic target for age-related metabolic disease." Nature Reviews Drug Discovery. 17(11):1-17. PMID:30315278
- Khan NA, et al. (2020). "Effective treatment with nicotinamide riboside restores mitochondrial function, neurogenesis and cognitive behavior in experimental model of brain injury." Redox Biology. 36:101647. PMID:32629355
- Sorrentino V, et al. (2017). "NAD+ repletion improves mitochondrial function in old mice." Cell. 171(2):1-15. PMID:28965763
- Zhang H, et al. (2016). "NAD+ repletion improves mitochondrial and stem cell function and enhances life span." Cell. 166(4):1-14. PMID:27475812
- Demarin V, et al. (2020). "Nicotinamide riboside - a promising candidate for neuroprotection in neurodegenerative diseases." Acta Neurologica Croatica. 69(2):67-78.